Background. Australia introduced universal 7-valent pneumococcal conjugate vaccine (PCV7) from 2005, replaced by 13-valent PCV (PCV13) in 2011, uniquely among high-income countries giving doses at 2, 4, and 6 months (3 + 0 schedule). Data on impact of a timely 3 + 0 PCV schedule with high coverage are sparse, with none for PCV13.
and ventilation tube insertions [9, 10] . Based on these data, the 3 + 0 schedule was continued [11] when PCV13 replaced PCV7 in mid-2011, a decision consistent with an independent systematic review of the effectiveness of differing PCV7 schedules that did not find significant advantages of 2 + 1 or 3 + 1 schedules over 3 + 0 [12] . However, a randomized trial of PCV13 schedules found lower antibody responses to some serotypes after primary sequence of 2 doses compared with 3 [13] , highlighting the need for postimplementation studies in countries using differing schedules to examine population-level impact of PCV13.
Although caution is needed in interpretation of postimplementation studies [3, 14] , Australian national IPD surveillance, like that in the UK and sentinel sites in the United States, fulfills quality criteria requiring stable, long-term enhanced surveillance capturing a large number of cases [7, 8] . Here we report impact on IPD 3.5 years post-PCV13 introduction, compared with an equivalent period post-PCV7 introduction, using a 3 + 0 schedule. The Australian experience complements reports from other settings using alternate PCV schedules, in the context of continuing global considerations about the optimum use of PCVs in national programs [15] .
METHODS

Data Sources and Period of Observation
Data from the national laboratory-based passive surveillance system, the National Notifiable Disease Surveillance System (NNDSS), with corresponding midyear resident population estimates from the Australian Bureau of Statistics as denominators, were used to derive age-and serotype-specific IPD incidence rates per 100 000 population. IPD has been a notifiable disease nationally in Australia since 2001, with constant and consistent capture of isolates since 2002. A confirmed IPD case is defined as isolation of S. pneumoniae by culture or detection of nucleic acid from a normally sterile body site. Serotyping of S. pneumoniae isolates is carried out in 3 reference laboratories. Data flow and data elements of the NNDSS have been described elsewhere [16] .
All cases of IPD with a date of diagnosis between 1 January 2002 and 31 December 2014, in individuals not identified as Indigenous from all jurisdictions except the Northern Territory were included in the study. These exclusions were due to earlier commencement of PCV7 funding for all Indigenous children nationally and programmatic use of PCV10 for 2 years between discontinuation of PCV7 and commencement of PCV13 in the Northern Territory.
The uptake and timeliness of PCV13 and PCV7 doses for all non-Indigenous children nationally were obtained from the Australian Childhood Immunisation Register (ACIR) [17] .
Design and Statistical Analysis
First, trends of incidence rates of IPD from 2002 to 2014, stratified by age and serotype categories, were examined. Case counts were adjusted for those where serotype was not available by proportional allocation according to the distribution of known serotypes in relevant year and age group. The serotypes included in each serotype category in the analyses are shown in Supplementary Table 1. The incidence rate ratio (IRR) post-vs pre-vaccine introduction was the metric used to measure vaccine impact, with confidence intervals (95% or 99%) calculated assuming a Poisson distribution. Average IPD incidence in the 3 years preceding vaccine introduction and the incidence in the last 12-month period of the 3.5 years since vaccine introduction were used to calculate pre-and post-vaccine introduction rates, respectively, for PCV7 and PCV13 and over the combined PCV period (Supplementary Table 2 ). Vaccine impact was examined for IPD due to selected individual serotypes (PCV7 types, 13-valent non-7-valent [13v-non7v] types, 6A and 6C) and relevant serotype categories and total IPD cases (Supplementary Table 3 ). Incidence rates of IPD for individual 13v-non7v types and 6C were calculated also for each post-PCV13 year.
Serotype replacement: To evaluate the emergence of serotypes causing replacement disease post-PCV13, IRRs were calculated for individual non-PCV13 serotypes and benchmarked against data for serotype 19A following PCV7 introduction.
In addition, cumulative proportions of annual average case counts for pre-and post-PCV13 periods by serotypes were compared, to better characterize changes in serotype coverage from vaccines currently in use in the NIP.
Pneumococcal meningitis: The impact of PCV13 on pneumococcal meningitis was separately evaluated in the age group in which it is most common (<2 years). This was of particular interest, as one rationale for preferring 3 + 0 schedule is potential for earlier attainment of highest achievable protection against meningitis, the most severe manifestation of IPD.
Vaccination Coverage
Vaccine uptake was calculated as proportions of children in 12-month birth cohorts (1 January to 31 December) recorded as receiving each PCV7/PCV13 dose by 12-month milestone age. Timeliness was assessed through examining the percentage of the cohort who received a third vaccine dose with a delay of <6 months (ie, at age 7-12 months) and ≥6 months (ie, at age ≥12 months). The uptake of PCV13 supplementary program was assessed with reference to eligible age cohorts.
Analyses were performed using IBM SPSS statistics software for Windows, version 22.0 (IBM, Armonk, New York).
Ethical Approval
Ethical approval was granted for the study on 26 A decline in incidence of PCV7 vaccine-type (VT) IPD is evident in all age groups in the first year post-PCV7 (2005), steepest in the youngest (<2 and 2-4 years) age groups ( Figure 1 ). From 2006, across all age groups, 13v-non7v-type IPD increased. Following PCV13 introduction, 13v-non7v-type IPD incidence declined substantially in children aged <2 years from the first year onward, with a slower decline, commencing in the second year, in those older. Among children aged <2 years, total IPD rapidly fell below the nadir previously reached post-PCV7, whereas in older age groups, total IPD either did not reach post-PCV7 nadir until year 2 or remained above it.
Declines in 13v-non7v-type IPD varied by serotype and age group (Table 1) . Serotype19A, which accounted for approximately 80% of PCV13-type IPD in children and approximately 40% in adults pre-PCV13 introduction, showed the most marked reduction, similar by age group, of almost 70% (IRR, 0.33; 95% CI, .27-.40) overall. IPD due to serotypes 1 and 6A also declined uniformly, with all-age reductions of >80%. In contrast, serotype 3 IPD incidence did not change appreciably in any age group and serotype 7F declined only in children aged Figure 1) . In contrast, for PCV13, the only individual serotype for which IRR estimates resembled those for PCV7 types was 19A.
Among children aged <2 years, after 9 years of PCV use, incidence of total IPD declined by 82% (IRR, 0.18; 95% CI, .15-.22) from baseline, compared with a 69% (IRR, 0.31; 95% CI, .24-.40) reduction among children aged 2-4 years ( Table 2) . Declines in IPD were greater in all age groups pre-to post-PCV7 compared with pre-to post-PCV13. For all age groups combined, incidence of all IPD declined by 47% over the 9 years of PCV use (IRR, 0.53; 95% CI, .50-.57). Reductions pre-to post-PCV7 were almost 4-fold greater (42%) than pre-to post-PCV13 (11%), despite significantly greater increases in NVT IPD post-PCV7 of 76% (IRR, 1.76; 95% CI, 1.58-1.96) vs 30% (IRR, 1.30; 95% CI, 1.16-1.45) post-PCV13.
Among non-PCV13 serotypes, statistically significant increases (P < .01) were found for 9N and 15A (Table 3) , restricted to persons aged ≥5 years. Increase post-PCV13 of serotype 23B also reached statistical significance when age groups were combined. In comparison, increases in 19A IPD post-PCV7 was highly significant in all 3 age groups.
Pneumococcal Meningitis
The overall decline of approximately 65% in pneumococcal meningitis in children aged <2 years due to PCV13 serotypes was similar to that of nonmeningitis IPD (Figure 2) . The proportion of cases occurring after 6 months of age (of total cases <2 years of age) pre-to post-PCV13 declined substantially more for VT pneumococcal meningitis (50% to 7%, P ≤ .005) than for VT nonmeningitis IPD (87% to 77%, P = .02). Serotype 19A drove this difference, with meningitis in children aged >6 months decreasing 100% (18 to 0 cases), compared with 75.8% (186 to 45) for nonmeningitis IPD. 
Vaccine Coverage
Among the cohort of non-Indigenous children born in 2013 (approximately 300 000), vaccine coverages of each dose of PCV13 by age 12 months were 93.1%, 92.8%, and 92.5%, marginally higher than for PCV7 in the 2010 birth cohort (92%, 91.4%, and 89.8%). The uptake of supplementary PCV13 dose was more than twice as high in those aged 12-23 months (47.9%) compared with 24-35 months (21.7%). With respect to timeliness of PCV13 third dose, <3% of children who received this dose did so after age 12 months, although around 18% received it between age 7 and 12 months, similar to timeliness for PCV7 dose 3. The proportion of PCV13 type IPD declined from 65.1% in the pre-to 39.4% in the post-PCV13 period in children aged <5 years and from 48.3% to 29.4% in adults aged ≥65 years ( Supplementary Figures 2 and 3) .
DISCUSSION
During the PCV7 era, using a 3 + 0 schedule, with rapid uptake among infants to >90%, and a concomitant catch-up program to age 24 months with uptake of around 60%, our data show substantial and sustained reductions in incidence of VT IPD in all age groups in Australia, consistent with previous reports [7, 8, 16] . Following PCV13 introduction in 2011, with similar coverage but lower uptake of the supplementary dose, only serotype 19A showed reductions in children and adults of similar magnitude to those post-PCV7. By the third post-PCV13 year, there was an 11% reduction in all-age total IPD incidence from pre-PCV13 baseline, compared with 42% decline in an equivalent PCV7 period. These 2 periods combined yielded an overall 47% decline in all-age total IPD. We can gain insight into the apparent differential impact under 3 + 0 schedule following PCV13, compared with PCV7, from clinical trial data on immunogenicity and carriage, and from comparison of our experience with that reported by England and Wales [18] and the United States [19] , countries with comparable pneumococcal epidemiology, vaccine coverage, and quality of postimplementation surveillance, but using alternate 2 + 1 and 3 + 1 vaccine schedules.
With respect to immunogenicity and carriage studies, data for PCV7 suggest that 3 primary doses compared to 2 in the first year of life gives greater protection at 1-7 months postvaccination, particularly against some vaccine serotypes [12, [20] [21] [22] . This is potentially important for early, direct protection against pneumococcal meningitis, the most severe manifestation of IPD that occurs more commonly in infancy. Importantly, in head-tohead immunogenicity trials, antibody responses for PCV13 for serotypes in common were somewhat lower than for PCV7 [23, 24] . For PCV13, serotype-specific functional antibody responses to 13v-non7v types varied more widely than did PCV7 serotypes in PCV7 recipients [24] . In a PCV13 immunogenicity trial, an 11-month booster dose in children primed with 3 doses at age 2, 4, and 6 months resulted in significantly increased antibody responses against 7F, but not 3 and 19A [13] . Higher antibody levels, achieved post-booster dose [13] , may be required for optimum reduction in susceptibility to IPD and carriage in the case of serotype 7F. Supporting this premise, antibody concentration needed for clinical protection against 7F IPD, estimated using postlicensure vaccine effectiveness data, was greater than the correlate of protection used for PCV13 licensure [25] .
The impact on IPD seen post-PCV7 in Australia was similar to that in the United Kingdom and the United States, despite different schedules [7] . Comparisons post-PCV13 are likely to be of even greater validity, as all 3 countries had high PCV13 coverage, and similar proportions of all-age total IPD caused by 13v-non7v serotypes at baseline. However, there were differences in IPD burden accounted for by specific 13v-non7v serotypes. In both the UK and United States, pre-PCV13 IPD due to 7F was of a similar magnitude to 19A [5, 19, 26] , whereas 19A dominated in Australia. Additionally, UK had higher serotype 1 IPD rates than Australia and the United States. This is an important consideration, as serotype 1 is more subject to temporal variation independent of vaccine pressure [27] . In contrast to Australia, the UK and United States reported reductions in 7F IPD post-PCV13 that were similar to 19A IPD, both in children and adults [18, 19] . Similarly, we observed little change in serotype 3 IPD, whereas both the UK and United States had decreases. Although the interpretation of both immunogenicity and effectiveness data for serotype 3 are more uncertain than for any other serotype [24, 25, [28] [29] [30] , a high case-to-colonization ratio and relatively high mortality make relative impact on serotype 3 disease by schedule an important consideration [31] . As a 3 + 0 and a 2 + 1 schedule require the same number of doses, this is arguably the more important comparative consideration. Overall, reductions in 13v-non7v IPD post-PCV13 were greater across all age groups in the UK than in ours, with the difference most marked between ages 5-65 years. Persistence of immunity from the booster dose extending beyond age 2 years, when the colonization levels for PCV13 types peak, is the most likely explanation for this difference [32] .
Our study has several limitations, related to its ecological design, which relies upon temporal associations post-vaccine introduction to infer causal links between changes in IPD incidence and vaccine uptake. As serotype specific incidence trends for individual 13v-non7v serotypes in years preceding PCV13 varied, we used mean incidence over 3 years (2008-2009 to 2010-2011) to provide a more stable pre-PCV13 baseline. Other factors that may impact on IPD incidence trends and serotype distribution, apart from the schedule used and vaccine coverage, include changes in prevalence of risk factors, and other pneumococcal vaccines used in the population at the same time, such as 23-valent pneumococcal polysaccharide vaccine in adults and in individuals with risk factors. Lower uptake of the supplementary PCV13 dose in children 12-36 months of age (approximately half that observed for PCV7 catch-up program [6] ) may also have contributed to lower impact of PCV13 compared to PCV7, through lesser impact on carriage.
The magnitude of incremental direct benefit from the use in elderly adults of PCV13 has been an important question following findings of the Community-Acquired Pneumonia in Adults (CAPiTA) Trial [33] . In our data, reductions in PCV13 VT IPD in age groups >5 years, including adults ≥65 years, were lower than reported by the UK and United States. As herd impact on nonbacteremic community-acquired pneumonia (CAP) appears to parallel changes in IPD [34, 35] , such impact may also be less with a 3 + 0 infant schedule [34, 36, 37] . If so, Australia could expect a greater incremental benefit on nonbacteremic pneumococcal CAP from a direct PCV13 program in older adults [34] , which is a major driver of cost-effectiveness of such a program.
Overall, our comparison of both PCV7 and PCV13 eras in Australia with the United States and the UK suggests that the 3 + 0 schedule yielded greater dividends for PCV7 than for PCV13, and lesser benefits from PCV13, than from alternate schedules. On this basis, replacement of 3 + 0 schedule with a 2 + 1 schedule appears likely to be cost-effective. The only question is whether 2-dose breakthrough cases, especially of meningitis, could occur between receipt of the second and third doses; this is relevant as we have seen near-disappearance of PCV13-type meningitis in infants aged ≥6 months. The 3 + 1 schedule would obviate this problem, but may not be cost-effective, unless there were substantially greater indirect effects in adults than the 2 + 1 schedule, particularly on nonbacteremic CAP. Waning immunity is also a concern with the 3 + 0 schedule, especially for serotype 1, which is more likely to occur in older age groups, as highlighted in an assessment of a 2 + 1 schedule with a booster dose at 9 months in South Africa [38] . Our findings suggest that the WHO-recommended 3 + 0 schedule, at earlier age points (6, 10, and 14 weeks compared with 6-8, 16, and 24 weeks in Australia) would, if adhered to, provide even less longer-term protection in older children against epidemics of especially serotype 1, which are more common in low-income settings. Continued monitoring of vaccine impact, combined with vaccine effectiveness assessments, will be needed to determine optimum spacing and number of doses to maximize protection from pneumococcal conjugate vaccines in the context of the epidemiologic and program implementation characteristics of each region.
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